Results 31 to 40 of about 180 (117)

Efficacy of Cladribine Tablets as a Treatment for People With Multiple Sclerosis: Protocol for the CLOBAS Study (Cladribine, a Multicenter, Long-term Efficacy and Biomarker Australian Study)

JMIR Research Protocols, 2021
BackgroundCladribine tablets (marketed as Mavenclad) are a new oral therapy, which has recently been listed on the pharmaceutical benefits scheme in Australia for the treatment of relapsing multiple sclerosis (MS).
Vicki E Maltby, Rodney A Lea, Mastura Monif, Marzena J Fabis-Pedrini, Katherine Buzzard, Tomas Kalincik, Allan G Kermode, Bruce Taylor, Suzanne Hodgkinson, Pamela McCombe, Helmut Butzkueven, Michael Barnett, Jeannette Lechner-Scott   +12 more
doaj   +1 more source

Recommendations for the use of cladribine tablets for the pathogenetic treatment of patients with highly active multiple sclerosis

Неврология, нейропсихиатрия, психосоматика, 2020
Currently, special attention is paid to timely treatment for active forms of multiple sclerosis (MS), especially for highly active MS (HAMS), in which there are ≥2 exacerbations and corresponding activity signs that are detected by magnetic resonance ...
K. Z. Bakhtiyarova, A. N. Boyko, Ya. V. Vlasov, Z. A. Goncharova, M. V. Davydovskaya, M. N. Zakharova, N. A. Malkova, A. I. Nilov, S. A. Sivertseva, N. N. Spirin, N. A. Totolyan, F. A. Khabirov, M. V. Shumilina   +12 more
doaj   +1 more source

Making Information About Cladribine Tablets Accessible to People with Multiple Sclerosis: A Patient-Survey-Led Narrative Review for Healthcare Professionals

Neurology and Therapy
Cladribine tablets have been granted marketing authorization in Europe and approved by the Food and Drug Administration (FDA) in the USA to treat relapsing forms of multiple sclerosis (MS).
Ardra Shephard, Laura Kolaczkowski, Noreen Barker, Donna Nahal, Celia Oreja-Guevara, Saúl Reyes, Helen Gray, Hashem Salloukh, Gavin Giovannoni   +8 more
doaj   +1 more source

Revealing the immune cell subtype reconstitution profile in patients from the CLARITY study using deconvolution algorithms after cladribine tablets treatment

Scientific Reports, 2023
Immune Cell Deconvolution methods utilizing gene expression profiling to quantify immune cells in tissues and blood are an appealing alternative to flow cytometry. Our objective was to investigate the applicability of deconvolution approaches in clinical
Irina Kalatskaya, Gavin Giovannoni, Thomas Leist, Joseph Cerra, Ursula Boschert, P. Alexander Rolfe   +5 more
doaj   +1 more source

Vaccination in multiple sclerosis patients treated with highly effective disease-modifying drugs: an overview with consideration of cladribine tablets

Therapeutic Advances in Neurological Disorders, 2021
Infectious diseases are an important consideration in autoimmune conditions such as multiple sclerosis. Infective episodes may trigger relapses and significantly deteriorate the course of the disease.
Ralf Gold, Gerd Fätkenheuer, Hans-Peter Hartung, Christoph Kleinschnitz, Reinhard Marks, Matthias Maschke, Antonios Bayas, Micha Löbermann, Uwe K. Zettl, Heinz Wiendl   +9 more
doaj   +1 more source

Cladribine treatment specifically affects peripheral blood memory B cell clones and clonal expansion in multiple sclerosis patients

Frontiers in Immunology, 2023
IntroductionB cells are acknowledged as crucial players in the pathogenesis of multiple sclerosis (MS). Several disease modifying drugs including cladribine have been shown to exert differential effects on peripheral blood B cell subsets. However, little
Christoph Ruschil, Christoph Ruschil, Gisela Gabernet, Constanze Louisa Kemmerer, Mohamed Ali Jarboui, Franziska Klose, Sven Poli, Sven Poli, Ulf Ziemann, Ulf Ziemann, Sven Nahnsen, Sven Nahnsen, Markus Christian Kowarik, Markus Christian Kowarik   +13 more
doaj   +1 more source

Confined B‐Cell Reconstruction and High T‐Cell Clonality Define Clinical Response to Cladribine Treatment

Annals of Neurology, Volume 99, Issue 5, Page 1166-1172, May 2026.
Cladribine tablets are approved for relapsing multiple sclerosis, mediating their clinical effect by moderately depleting lymphocytes. In a prospective, monocentric study including 22 patients completing 2 annual cycles of cladribine, B‐ and T‐cell receptor repertoires and relapse activity were assessed at baseline and after 24 months. T‐cell clonality
Tilman Schneider‐Hohendorf, Maria Eveslage, Timo Wirth, Christian Wünsch, Eva M. Schumann, Jan D. Lünemann, Heinz Wiendl, Luisa Klotz, Nicholas Schwab   +8 more
wiley   +1 more source

Experience of cladribine tablets usage in the treatment of multiple sclerosis in the Multiple Sclerosis Centre of the Khanty-Mansi Autonomous Area — Yugra

Неврология, нейропсихиатрия, психосоматика
Cladribine is a tablet preparation for the treatment of relapsing-remitting multiple sclerosis (RRMS), which is used as an immune reconstitution therapy.
A. A. Sokolova, L. I. Anischenko, L. S. Zemlyanushin, E. A. Rubtsova   +3 more
doaj   +1 more source

The Contribution to the Assignment of Defined Daily Dose (DDD) to Antineoplastic Drugs of the Italian Working Group on DDD

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 5, May 2026.
ABSTRACT Purpose To report the experience of the Italian Working Group on DDD (Ita‐DDD‐wg) in assigning DDDs to a list of antineoplastic agents. Methods Active substances from the ATC L01 group with no assigned DDD and reimbursed at least once during 2021 by the Italian Healthcare Service were identified.
Angela Boccia, Giulia Hyeraci, Anna Girardi, Rosa Gini, Gianluca Trifirò, Ylenia Ingrasciotta, Andrea Spini, Valentina Ientile, Elisabetta Poluzzi, Giampiero Mazzaglia, Ippazio Cosimo Antonazzo, Casula Manuela, Elena Tragni, Olivia Leoni, Arianna Mazzone, Michele Ercolanoni, Martina Zanforlini, Ursula Kirchmayer, Belleudi Valeria, Marco Finocchietti, Francesco Barone‐Adesi, Giuseppe Roberto   +21 more
wiley   +1 more source

Neuro‐Immune Crosstalk: Molecular Mechanisms, Biological Functions, Diseases, and Therapeutic Targets

MedComm, Volume 7, Issue 2, February 2026.
Neurons, immune cells, and other cellular components within the disease microenvironment (such as stromal cells and tumor cells) constitute a dynamically evolving ecosystem. Neurons directly modulate immune cell activity and inflammatory responses through the release of neurotransmitters (e.g., norepinephrine and CGRP), while also promoting tumor ...
Xin Guo, Hui Liu, Yu‐Jing Song, Jian‐Hua Wang, Danfeng Liu, Zhi‐Wei Zheng, Jia‐Jun Li, Boya Li, An Song, Wei He, Lei‐Lei Yang, Shuo Wang   +11 more
wiley   +1 more source